{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000059","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.492706+00:00","generated_at":"2026-06-01T04:07:33.424068+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Keros Therapeutics files prospectus supplement for up to $350M at-the-market stock offering","bullets":["Filed prospectus supplement on June 17, 2024 to sell up to $350 million of common stock via ATM program.","Leerink Partners acts as sales agent, earning a commission of up to 3.0% of gross proceeds.","Sales may be made directly on the Nasdaq Global Market; company not obligated to sell any shares.","Original sales agreement dated May 3, 2021; shelf registration statement effective May 3, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000059","json":"https://secwatch.observer/filing/0001664710-24-000059.json","markdown":"https://secwatch.observer/filing/0001664710-24-000059.md","text":"https://secwatch.observer/filing/0001664710-24-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000059/0001664710-24-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000059/kros-20240617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:07:33.424068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}